Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Monoclonal Antibodies Report Part I' returned 79 results - Page 1 of 4   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Next-Generation Protein and Peptide Therapeutics   Business Insights, Aug 2011, Pages: 192 and benefits - Understand the limitations of monoclonal antibodies, how these relate to molecular structure, and which protein alternatives may offer solutions. - Discover the most innovative delivery Royalty Rates for Pharmaceuticals & Biotechnology, 7th Edition   Intellectual Property Research Associates IPRA, Sep 2010, Pages: 360 and pharmaceutical intellectual property transfers. This report is organized into two parts. The first part covers the theory associated with deriving royalty rates. An overview of intellectual property value Therapeutic Proteins Market to 2017 - High Demand for Monoclonal Antibodies will Drive the Market   GBI Research, Sep 2011, Pages: 142 , monoclonal antibodies have been included as a part of therapeutic proteins market along with blood factors, colony stimulating factors, erythropoietins, human growth hormone, insulin and interferons. Moderate Future of Red Biotechnology in China   CCM International Limited, April 2010, Pages: 178 of red biotechnology industry in China III-1 Gene recombinant drugs III-1.1 Erythropoietin(EPO) III-1.2 Insulin III-1.3 G-CSF III-1.4 Rh-GH III-1.5 Interferon III-1.6 Anti-tumor monoclonal antibody Neuroprotection - Drugs, Markets and Companies   Jain PharmaBiotech, Feb 2012, Pages: 628 Anti-HMGB1 monoclonal antibody Antioxidant approaches Carnosine as a neuroprotective in stroke Dehydroascorbic acid Tocotrienols Uric acid Antiglutamate compounds MRZ 2/576 L-Phenylalanine The 2011 Report on AntiCD20 Monoclonal Antibodies: World Market Segmentation by City   ICON Group International, Jan 2011, Pages: 329 Market Potential Estimation Methodology Overview This study covers the world outlook for AntiCD20 Monoclonal antibodies across more than 2000 cities. For the year reported, estimates are given The 2011 Report on Monoclonal Antibody (MAb)-Based Products: World Market Segmentation by City   ICON Group International, Jan 2011, Pages: 329 at large (without needing to know the specific parts that went into the whole in the first place). Given this caveat, in this report we define the sales of Monoclonal Antibody (MAb)-based products The 2011 Report on Therapeutic Monoclonal Antibody (Mab)-Based Products: World Market Segmentation by City   ICON Group International, Jan 2011, Pages: 329 the specific parts that went into the whole in the first place). Given this caveat, in this report we define the sales of therapeutic Monoclonal Antibody (Mab)-based products as including all commonly Autoimmune Disease Therapeutics - Global Strategic Business Report   Global Industry Analysts, Inc., Oct 2011, Pages: 749 Designation for Prochymal from FDA 68 Immunomedics Obtains US Patent for Immunotherapy 68 Biogen Idec Introduces Monoclonal Antibody Tysabri in India 69 Merck Serono Unveils Pre-Filled Pen RebiDose™ in UK The 2011-2016 Outlook for Therapeutic Monoclonal Antibody (Mab)-Based Products in Asia & the Middle East   ICON Group International, Jan 2011, Pages: 62 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for therapeutic monoclonal antibody (mab)-based products The 2011-2016 Outlook for AntiCD20 Monoclonal Antibodies in Africa   ICON Group International, Jan 2011, Pages: 56 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for anticd20 monoclonal antibodies is not actual The 2011-2016 Outlook for Monoclonal Antibody (MAb)-Based Products in Africa   ICON Group International, Jan 2011, Pages: 58 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for monoclonal antibody (mab)-based products is not actual The 2011-2016 Outlook for Therapeutic Monoclonal Antibody (Mab)-Based Products in Africa   ICON Group International, Jan 2011, Pages: 64 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for therapeutic monoclonal antibody (mab)-based products The 2011-2016 Outlook for Monoclonal Antibody (MAb)-Based Products in Asia & Oceana   ICON Group International, Jan 2011, Pages: 56 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for monoclonal antibody (mab)-based products is not actual The 2011-2016 Outlook for AntiCD20 Monoclonal Antibodies in Asia   ICON Group International, Jan 2011, Pages: 38 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for anticd20 monoclonal antibodies is not actual The 2011-2016 Outlook for AntiCD20 Monoclonal Antibodies in Europe & the Middle East   ICON Group International, Jan 2011, Pages: 71 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for anticd20 monoclonal antibodies is not actual The 2011-2016 Outlook for Monoclonal Antibody (MAb)-Based Products in Europe   ICON Group International, Jan 2011, Pages: 55 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for monoclonal antibody (mab)-based products is not actual The 2011-2016 Outlook for Therapeutic Monoclonal Antibody (Mab)-Based Products in Europe   ICON Group International, Jan 2011, Pages: 57 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for therapeutic monoclonal antibody (mab)-based products The 2011-2016 Outlook for AntiCD20 Monoclonal Antibodies in Latin America   ICON Group International, Jan 2011, Pages: 35 countries and the world at large (without needing to know the specific parts that went into the whole in the first place). Given this caveat, in this report we define AntiCD20 Monoclonal antibodies The 2011-2016 Outlook for Monoclonal Antibody (MAb)-Based Products in Latin America   ICON Group International, Jan 2011, Pages: 35 smaller than the P.I.E. of levels at lower levels of the same value chain, assuming all levels maintain minimum profitability). The latent demand for monoclonal antibody (mab)-based products is not actual Results:  First -   Prev -   1 -   2 -   3 -   4 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-800-526-8630 (US/Canada Toll Free)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets1    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network